Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase 1 Study of VELA-101 in Adult Participants
Sponsor: Ursa Medicines
Summary
This is a first-in-human (FIH), multicenter, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of VELA-101, following single-ascending doses via subcutaneous (SC) administration.
Official title: A Phase 1, Randomised, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VELA-101 in Adult Participants
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2026-11
Completion Date
2027-09
Last Updated
2026-10-07
Healthy Volunteers
Yes
Conditions
Interventions
VELA-101
subcutaneous injection
Placebo
subcutaneous injection
Locations (2)
University of Sunshine Coast
Morayfield, Queensland, Australia
Linear Clinical Research
Nedlands, Western Australia, Australia